Determination of a HLA II Promiscuous Peptide Cocktail as Potential Vaccine Against EBV Latency II Malignancies
Authors:
- Stéphane DepilSDStéphane Depil
- Olivier MoralèsOMOlivier Moralès
- Florence A. CastelliFCFlorence A. Castelli
- Nadira DelhemNDNadira Delhem
- Violaine FrançoisVFViolaine François
- Bertrand GeorgesBGBertrand Georges
- Françoise DufosséFDFrançoise Dufossé
- Franck MorschhauserFMFranck Morschhauser
- Juergen HammerJHJuergen Hammer
- Bernard MaillèreBMBernard Maillère
- Claude AuriaultCAClaude Auriault
- Véronique PancréVPVéronique Pancré
- 1 February 2007
- journal article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 30 (2) , 215-226
Abstract
The Epstein-Barr virus (EBV) is associated with several malignant diseases, which can be distinguished by their patterns of viral latent gene expression. The latency II program is limited to the expression of the nonimmunodominant antigens EBNA1, LMP1 and LMP2 and is seen in EBV-positive Hodgkin disease, nasopharyngeal carcinomas, and peripheral T/NK-cell lymphomas. CD4+ T cells may play a crucial role in controlling these EBV latency II malignancies. In this study, we used the prediction software TEPITOPE to predict promiscuous major histocompatibility complex class II epitopes derived from the latency II antigens EBNA1, LMP1, and LMP2. The predicted peptides were then submitted to peptide-binding assays on HLA II purified molecules, which allowed the selection of 6 peptides (EBNA1: 3; LMP1: 1; and LMP2: 2) with a highly promiscuous capability of binding. This peptide cocktail was immunogenic in a model of HLA-DR1 transgenic mice, leading to a specific cellular and humoral TH1 response. The peptides were also recognized by human CD4+ T cells from individuals expressing various HLA II genotypes. This promiscuous peptide cocktail could be immunogenic in the majority of the population and may be used as a peptide-based vaccine in EBV latency II malignancies.Keywords
This publication has 65 references indexed in Scilit:
- The human T cell immune response to Epstein-Barr virusThe International Journal of Developmental Biology, 2005
- Epitope-specific Evolution of Human CD8+ T Cell Responses from Primary to Persistent Phases of Epstein-Barr Virus InfectionJournal of Experimental Medicine, 2002
- Identification and prevalence of CD8+ T‐cell responses directed against Epstein‐Barr virus‐encoded latent membrane protein 1 and latent membrane protein 2International Journal of Cancer, 2002
- Differential Immunogenicity of Epstein-Barr Virus Latent-Cycle Proteins for Human CD4+T-Helper 1 ResponsesJournal of Virology, 2001
- Role of Cytotoxic T Lymphocytes in Epstein-Barr Virus-Associated DiseasesAnnual Review of Microbiology, 2000
- Epstein–Barr Virus InfectionNew England Journal of Medicine, 2000
- HUMAN CYTOTOXIC T LYMPHOCYTE RESPONSES TO EPSTEIN-BARR VIRUS INFECTIONAnnual Review of Immunology, 1997
- Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.Journal of Experimental Medicine, 1996
- Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.Journal of Experimental Medicine, 1992
- Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.Journal of Experimental Medicine, 1992